Chapter 6: Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. Clinical Management of Pediatric COVID-19: An international Perspective and Practical Guide

Helen Groves, Shaun K. Morris, Upton Allen

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

Abstract

SARS-CoV-2 infection is typically less severe in children and adolescents compared to adults and the vast majority of pediatric patients do not require any care or will recover with supportive care only. In the absence of adequate pediatric data, most recommendations for children and adolescents are based on efficacy and safety data from adult studies and the optimal approach to the management of pediatric patients with acute COVID-19 is not yet determined. A number of national pediatric guidelines are available, and these continue to evolve rapidly with the emergence of new study information. As of January 2022 data from clinical trials in adult patients suggested a benefit to mortality outcomes with the use of dexamethasone, tocilizumab, and janus kinase inhibitors in certain subgroups of patients, potential benefit from the use of remdesivir, as well as emerging evidence for COVID-19 specific monoclonal antibody use. Given the paucity of pediatric data, the use of specific therapy in the context of acute COVID-19 is not considered routine, and decisions regarding specific therapy use are made on discussion with the multidisciplinary clinical team including infectious diseases experts. Guidelines recommend where possible children should be enrolled in available clinical trials. On a case-by-case basis, guidelines suggest specific therapy may be considered appropriate in children with severe or critical COVID-19 or in cases of mild and moderate disease where risk factors for progression to the severe disease exist. This chapter provides an overview of available evidence as of January 2022 and guidance on supportive care and the use of specific therapies for the management of both hospitalized and non hospitalized pediatric patients with acute COVID-19. It should be noted that due to the rapid evolution of evidence, regularly updated local, national and regional guidance documents should be consulted when determining treatment of pediatric patients with acute COVID-19.
Original languageEnglish
Title of host publicationClinical Management of Pediatric COVID-19
Subtitle of host publicationAn International Perspective and Practical Guide
PublisherElsevier
Chapter6
Pages99-139
Edition1st
ISBN (Print)978-0-323-95059-6
DOIs
Publication statusPublished - Jan 2023

Fingerprint

Dive into the research topics of 'Chapter 6: Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. Clinical Management of Pediatric COVID-19: An international Perspective and Practical Guide'. Together they form a unique fingerprint.

Cite this